Singapore markets closed

ABBV Jun 2023 175.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.8700+0.0600 (+7.41%)
At close: 03:41PM EDT
Full screen
Previous close0.8100
Expiry date2023-06-16
Day's range0.8100 - 0.8700
Contract rangeN/A
Open interest1.83k
  • Motley Fool

    Could This Drug News Lift AbbVie's Stock?

    Consider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $21.2 billion in revenue in 2022. The good news is that AbbVie knew this day would come and has been preparing. SLE is an autoimmune disease that affects multiple organs of the body.

  • Motley Fool

    The Top Healthcare Stocks to Buy With $100

    A common misconception is that you need a lot of money to invest in the stock market. Let's look at three healthcare stocks that can be purchased for $100 and have good prospects to grow over time. The stock hasn't been off to a great start this year, dipping 18%, but the odds look pretty good for the company in the near future.

  • Motley Fool

    This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie

    AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC). Let's examine the data from the clinical trial and the U.S. UC market to resolve this question. Ulcerative colitis is a form of inflammatory bowel disease (IBD) that causes damage to the gastrointestinal (GI) tract.